These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 36897758)
1. PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Gupta S; Halabi S; Yang Q; Roy A; Tubbs A; Gore Y; George DJ; Nanus DM; Antonarakis ES; Danila DC; Szmulewitz RZ; Wenstrup R; Armstrong AJ Clin Cancer Res; 2023 May; 29(10):1929-1937. PubMed ID: 36897758 [TBL] [Abstract][Full Text] [Related]
2. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581 [TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193 [TBL] [Abstract][Full Text] [Related]
5. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633 [TBL] [Abstract][Full Text] [Related]
6. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest. Liu HE; Vuppalapaty M; Hoerner CR; Bergstrom CP; Chiu M; Lemaire C; Che J; Kaur A; Dimmick A; Liu S; Metzner TJ; Araya M; Crouse S; Sprenger-Haussels M; Schlumpberger M; Leppert JT; Hauch S; Sollier E; Fan AC BMC Cancer; 2024 Apr; 24(1):482. PubMed ID: 38627648 [TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885 [TBL] [Abstract][Full Text] [Related]
8. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577 [TBL] [Abstract][Full Text] [Related]
9. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer. Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641 [TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216 [TBL] [Abstract][Full Text] [Related]
11. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549 [TBL] [Abstract][Full Text] [Related]
12. Assessment of Total, PTEN Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297 [TBL] [Abstract][Full Text] [Related]
13. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355 [TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Brown LC; Halabi S; Schonhoft JD; Yang Q; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Barnett ES; Carbone EA; Zhao JL; Healy P; Anand M; Gill A; Jendrisak A; Berry WR; Gupta S; Gregory SG; Wenstrup R; Antonarakis ES; George DJ; Scher HI; Armstrong AJ Clin Cancer Res; 2021 Jul; 27(14):4077-4088. PubMed ID: 33820782 [TBL] [Abstract][Full Text] [Related]
15. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID; BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967 [TBL] [Abstract][Full Text] [Related]
16. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer. Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689 [TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010 [No Abstract] [Full Text] [Related]
18. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Petrylak DP; Vogelzang NJ; Chatta K; Fleming MT; Smith DC; Appleman LJ; Hussain A; Modiano M; Singh P; Tagawa ST; Gore I; McClay EF; Mega AE; Sartor AO; Somer B; Wadlow R; Shore ND; Olson WC; Stambler N; DiPippo VA; Israel RJ Prostate; 2020 Jan; 80(1):99-108. PubMed ID: 31742767 [TBL] [Abstract][Full Text] [Related]
19. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Haas NB; LaRiviere MJ; Buckingham TH; Cherkas Y; Calara-Nielsen K; Foulk B; Patel J; Gross S; Smirnov D; Vaughn DJ; Amaravadi R; Wellen KE; Savitch SL; Majmundar KJ; Black TA; Yee SS; He M; Min EJ; Long Q; Jones JO; Pal SK; Carpenter EL Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):448-456. PubMed ID: 33009489 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients. Gu T; Li J; Chen T; Zhu Q; Ding J Int Urol Nephrol; 2023 Apr; 55(4):883-892. PubMed ID: 36709467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]